Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GPCR |
---|---|---|
09:32 ET | 10517 | 54.985 |
09:34 ET | 4620 | 54.995 |
09:36 ET | 15651 | 53.6 |
09:38 ET | 4134 | 53.89 |
09:39 ET | 57732 | 53.965 |
09:41 ET | 23226 | 53.4 |
09:43 ET | 9337 | 53.75 |
09:45 ET | 51784 | 53.16 |
09:48 ET | 21954 | 53.73 |
09:50 ET | 24046 | 53.355 |
09:52 ET | 14130 | 54.115 |
09:54 ET | 8239 | 53.715 |
09:56 ET | 3802 | 53.72 |
09:57 ET | 5603 | 53.36 |
09:59 ET | 19505 | 53.39 |
10:01 ET | 2860 | 53.38 |
10:03 ET | 486 | 53.57 |
10:06 ET | 4400 | 53.695 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Structure Therapeutics Inc | 1.6B | -23.1x | --- |
Edgewise Therapeutics Inc | 1.6B | -11.3x | --- |
Neumora Therapeutics Inc | 1.6B | -4.0x | --- |
Kura Oncology Inc | 1.6B | -10.0x | --- |
Syndax Pharmaceuticals Inc | 1.6B | -6.0x | --- |
Sana Biotechnology Inc | 1.7B | -4.7x | --- |
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 46.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.32 |
Book Value | $9.76 |
P/E Ratio | -23.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.